MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
6.63
-0.24
-3.43%
Opening 15:44 11/28 EST
OPEN
6.76
PREV CLOSE
6.86
HIGH
7.02
LOW
6.60
VOLUME
643.48K
TURNOVER
2.36M
52 WEEK HIGH
9.13
52 WEEK LOW
3.280
MARKET CAP
488.15M
P/E (TTM)
-1.4542
1D
5D
1M
3M
1Y
5Y
Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) latest 9.4% decline adds to one-year losses, institutional investors may consider drastic measures
To get a sense of who is truly in control of Esperion Therapeutics, Inc. ( NASDAQ:ESPR ), it is important to understand...
Simply Wall St. · 11/21 11:25
Esperion Therapeutics Promotes Ben Halladay to Chief Financial Officer
Esperion Therapeutics Promotes Ben Halladay to Chief Financial Officer
MT Newswires · 11/17 06:03
Ben Halladay appointed CFO of Esperion
Seekingalpha · 11/16 21:14
Esperion Therapeutics's Return On Capital Employed Insights
Benzinga · 11/09 14:54
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
– Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs – – Esperion Leadership Will Provide Overview of its Investigational Pipeline, Planned Scientific Focus, and Future Growth Drivers – – Virtual...
GlobeNewswire · 11/09 13:00
Catalyst watch: CPI downtick, election ripples, Disney and Rivian earnings, Roblox conference call
Seekingalpha · 11/04 17:30
Wall Street Analysts Think Esperion Therapeutics (ESPR) Could Surge 32%: Read This Before Placing a Bet
The consensus price target hints at a 32.5% upside potential for Esperion Therapeutics (ESPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will w...
Zacks · 11/04 13:55
Esperion to Participate in Jefferies London Healthcare Conference
ANN ARBOR, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at the Jefferies London Healthcare Conference on Wednesday, November 16th, 2022. Event:Jefferies London Healthc...
GlobeNewswire · 11/02 12:00
More
About ESPR
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Webull offers kinds of Esperion Therapeutics Inc stock information, including NASDAQ:ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.